An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project

Massimo Andreoni, Simone Marcotullio, Vincenzo Puro, Gabriella De Carli, Giuseppe Tambussi, Silvia Nozza, Andrea Gori, Stefano Rusconi, Maria Mercedes Santoro, Massimo Clementi, Carlo Federico Perno, Antonella D'Arminio Monforte, Franco Maggiolo, Antonella Castagna, Andrea De Luca, Massimo Galli, Andrea Giacomelli, Marco Borderi, Giovanni Guaraldi, Andrea CalcagnoGiovanni Di Perri, Stefano Bonora, Cristina Mussini, Antonio Di Biagio, Massimo Puoti, Raffaele Bruno, Valentina Zuccaro, Andrea Antinori, Paola Cinque, Davide Croce, Umberto Restelli, Giuliano Rizzardini, Adriano Lazzarin

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)


Thanks to the development of antiretroviral agents to control HIV replication, HIV infection has turned from a fatal disease into a treatable chronic infection. The present work collects the opinions of several experts on the efficacy and safety of recently approved second generation of integrase inhibitors and, in particular, on the role of this new class of drugs in antiretroviral therapy. The availability of new therapeutic options represents an opportunity to ameliorate the efficacy of cART in controlling HIV replication also within viral reservoirs. The personalization of the treatment driven mainly by the management of comorbidities, HIV-HCV co-infections and aging, will be easier with antiretroviral drugs without drug-drug interactions and with a better toxicity and tolerability profile. Future assessment of economic impact for the introduction of new innovative drugs in the field of antiretroviral therapy will likely need some degree of adjustment of the evaluation criteria of costs and benefit which are currently based almost exclusively on morbidity and mortality.
Lingua originaleEnglish
pagine (da-a)443-490
Numero di pagine48
RivistaNew Microbiologica
Stato di pubblicazionePubblicato - 2015


  • HIV
  • Integrase Inhibitors
  • PEP
  • PrEP


Entra nei temi di ricerca di 'An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project'. Insieme formano una fingerprint unica.

Cita questo